Study Suggests GLP-1 Weight-Loss Drugs May Extend Lifespan in Mice
GLP-1 medications, including semaglutide—marketed as Ozempic and Wegovy—have gained significant attention for their roles in managing obesity and type 2 diabetes. These drugs work by mimicking a natural hormone that promotes feelings of fullness and helps regulate blood sugar levels. Recently, a study published in the journal Nature on September 2 has unveiled a potential new benefit of these medications: their ability to slow aging. Researchers administered daily injections of semaglutide to elderly female mice, which are roughly equivalent in age to 60-year-old women, and observed a notable increase in their lifespan. The median lifespan of the mice receiving semaglutide was 834 days, compared to 742 days for those receiving saline injections, marking a 12 percent increase in longevity.
The study, led by Danica Chen, an aging biologist at the University of California, Berkeley, sought to explore whether GLP-1 medications could replicate the effects of calorie restriction, a known method for extending lifespan. Chen noted that while calorie restriction is effective, it is often difficult for people to maintain. The hypothesis was that GLP-1 drugs, by reducing appetite, might provide similar benefits without the constant hunger associated with strict dieting.
To test this theory, the researchers injected 20-month-old female mice with semaglutide daily for the remainder of their lives. The treated mice not only lived longer but also exhibited improved physical and cognitive abilities. After three months of treatment, these mice were more active and curious compared to the control group, performing better in physical tasks such as balancing on rotating rods, running longer distances on a treadmill, and navigating mazes more efficiently. Additionally, molecular analyses revealed that the tissues of the semaglutide-treated mice showed reduced signs of aging, including less DNA damage and inflammation.
In comparing the effects of semaglutide to calorie restriction, the researchers found that both approaches led to similar improvements in lifespan and performance in endurance and motor coordination tests. However, the semaglutide-treated mice outperformed their calorie-restricted counterparts in memory and exploratory tasks, suggesting that the drug's benefits extend beyond mere calorie reduction. Despite these promising findings, the underlying mechanisms driving semaglutide's effects on aging remain unclear.
Experts caution that while the study presents a positive signal, further research is necessary, particularly since the study only involved female mice. Michael Corley, an aging biologist at the University of California, San Diego, emphasized the need for more extensive testing to determine whether these findings can be generalized across genders. Additionally, there are clinical concerns regarding the potential for muscle loss associated with GLP-1 use, which is particularly troubling for older adults who naturally experience muscle mass decline as they age. Matt Mendoza, a neuroscientist at the University of Texas Medical Branch, highlighted the importance of exercise to mitigate muscle loss when considering the use of semaglutide for longevity.




